Fairlie
David Fairlie, Springwood AU
Patent application number | Description | Published |
---|---|---|
20090004264 | METHODS FOR TREATING AND AMELIORATING THE SYMPTONS OF INFLAMMATORY BOWEL DISEASES - This invention relates to methods of treatment of inflammatory bowel disease, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the methods of the invention are disclosed. | 01-01-2009 |
20090203760 | CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS - The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions. | 08-13-2009 |
20100267639 | TREATMENT OF OSTEOARTHRITIS - This invention relates to methods of treatment of osteoarthritis, and especially to treatment of this condition with cyclic peptidic and peptidomimetic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists of the C5a receptor, and are active against C5a receptors on polymorphonuclear leukocytes and macrophages. Particularly preferred compounds for use in the invention are disclosed. | 10-21-2010 |
20100331236 | CYCLIC PEPTIDES AS G-PROTEIN COUPLED RECEPTOR ANTAGONISTS - The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions. | 12-30-2010 |
20120302493 | Cyclic Peptides As G-Protein Coupled Receptor Antagonists - The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions. | 11-29-2012 |
20130005644 | CYCLIC AGONISTS AND ANTAGONISTS OF C5A RECEPTORS AND G PROTEIN-COUPLED RECEPTORS - The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions. | 01-03-2013 |
David Fairlie, Mt. Ommaney AU
Patent application number | Description | Published |
---|---|---|
20130157928 | NOCICEPTIN MIMETICS - The present invention relates to nociceptin peptide mimetics that have α-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described. | 06-20-2013 |
20140302069 | MODULATORS OF C3A RECEPTORS - Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated cardiovascular diseases are described. The use of the compounds in stimulating or suppressing an immune response is also described together with pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts. | 10-09-2014 |
David Fairlie, Brisbane AU
Patent application number | Description | Published |
---|---|---|
20140315796 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS - The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities. | 10-23-2014 |
David P. Fairlie, Springwood AU
Patent application number | Description | Published |
---|---|---|
20120238507 | ALPHA HELICAL MIMICS, THEIR USES AND METHODS FOR THEIR PRODUCTION - Disclosed are short chain peptides that are constrained to adopt an alpha helicial conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides. Also disclosed is the use of these peptides for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. The peptides find use in mimicking naturally occurring peptides or proteins or in preparing new materials. | 09-20-2012 |
David P. Fairlie, Queensland AU
Patent application number | Description | Published |
---|---|---|
20080242598 | Alpha Helical Mimics, Their Uses and Methods For Their Production - This invention discloses short chain peptides that have been constrained to adopt an alpha helical conformation and their use as alpha helical scaffolds for directing amino acid side chains into positions analogous to those found in longer chain alpha helical peptides and for attaching peptidic or non-peptidic appendages in order to mimic side chains of longer alpha helical peptides. More particularly the invention discloses alpha helical cyclic pentapeptides and their use as alpha helical scaffolds or macrocyclic alpha helical modules, either alone, or within longer chain peptides or attached to other macrocyclic peptides or attached to non-peptidic structures, for the purpose of mimicking naturally occurring peptides or proteins, and as agonists or antagonists of the biological activity of naturally-occurring peptides or proteins or for the preparation of new materials. | 10-02-2008 |
David Paul Fairlie, Brisbane AU
Patent application number | Description | Published |
---|---|---|
20130184226 | MODULATIONS OF PROTEASE ACTIVATED RECEPTORS - The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of—or susceptible to—a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity. | 07-18-2013 |
20150038402 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS - The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor- | 02-05-2015 |
Jane Fairlie, Spalding GB
Patent application number | Description | Published |
---|---|---|
20120151645 | Blackberry Plant Named 'Reuben' - This invention relates to a new and distinct variety of blackberry plant named ‘Reuben’, which is primarily characterized by its primocane fruiting habit, large fruit size, high quality, and high productivity, is disclosed. | 06-14-2012 |
Walter Douglas Fairlie, Montmorency AU
Patent application number | Description | Published |
---|---|---|
20090048164 | THERAPEUTIC PRO-APOPTOTIC BH3-LIKE MOLECULES AND METHODS FOR GENERATING AND/OR SELECTING THE SAME - The present invention relates generally to therapeutic molecules which are useful for modulating apoptosis in a target cell or cell population. More particularly, the present invention provides therapeutic agents which inhibit pro-survival molecules and which are capable of inducing or facilitating apoptosis of a target cell or cell population such as cancer cells. The present invention further provides methods for generating or selecting the therapeutic molecules and pharmaceutical compositions comprising the therapeutic molecules. | 02-19-2009 |